Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18643159 | 0.98 | MAP3K14 (0.48) | MAP3K14MAPTCRBNCYP19A1MEN1 | |
| SCHEMBL11384807 | 0.83 | MAP3K14 (0.52) | MAP3K14MAPTCRBNCYP19A1MEN1 | |
| SCHEMBL11384813 | 0.83 | MAP3K14 (0.52) | MAP3K14MAPTCRBNCYP19A1MEN1 | |
| SCHEMBL5909391 | 0.78 | MAP3K14 (0.55) | MAP3K14MAPTCRBNCYP19A1MEN1 | |
| SCHEMBL5556075 | 0.76 | MAP3K14 (0.41) | MAP3K14CRBN | |
| Bicarbonate SCHEMBL28708130 | 0.76 | MAP3K14 (0.34) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL28541981 | 0.75 | MAP3K14 (0.46) | MAP3K14MAPTCRBNKMT2AALDH1A1 | |
| SCHEMBL18261248 | 0.71 | MAP3K14 (0.35) | MAP3K14 | |
| SCHEMBL9484357 | 0.71 | MAP3K14 (0.35) | MAP3K14CRBN | |
| SCHEMBL9063186 | 0.71 | MAPT (0.43) | MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220072149-A1 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | SAPREME TECHNOLOGIES B.V. (NL) | 2022-03-10 | — | — | US | disclosed |
| CN-109148953-A | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2019-01-04 | — | — | CN | disclosed |
| CN-100371407-C | Double-sided pressure-sensitive adhesive tape or sheet and process of producing the same | NITTO DENKO CORP (JP) | 2008-02-27 | — | — | CN | disclosed |
| CN-1616576-A | Double-sided pressure-sensitive adhesive tape or sheet and process of producing the same | NITTO DENKO CORP (JP) | 2005-05-18 | — | — | CN | disclosed |
| US-4057432-A | PHOTOGRAPHIC COUPLERS | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JA) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072149-A1 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | CD40, TNFSF11, TNFSF10 | MAP3K14 4641/4885MAPT 3226/4885CRBN 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.